Biotherapy for cutaneous squamous cell carcinoma
- VernacularTitle:皮肤鳞状细胞癌生物治疗进展
- Author:
Xiang JI
1
;
Daguang WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma, squamous cell; Skin; Molecular targeted therapy; Immunotherapy; Biotherapy
- From: Chinese Journal of Dermatology 2025;58(1):79-83
- CountryChina
- Language:Chinese
- Abstract: Since cemiplimab was approved by United States Food and Drug Administration in 2018, anti-programmed cell death receptor-1 antibodies have been considered as the first-line systemic therapy for advanced cutaneous squamous cell carcinoma. This review focuses on current clinical application of targeted therapy, immunotherapy, targeted immunotherapy and gene therapy for cutaneous squamous cell carcinoma.
